Drugmakers’ blaming of higher prices on pharmacy benefit managers is a “straw man argument,” Devon Herrick writes. “Drug plans do their best to hold down drug prices for plan sponsors — their clients — which occasionally makes them unpopular with drugmakers and pharmacy owners.” Competition is the key to lowering drug costs, and the 21st Century Cures Act, which streamlines the approval process for new drugs, is a good start, but more can be done, Herrick writes.